Dr. Michael Topf, an associate professor specializing in Otolaryngology-Head and Neck Surgery at Vanderbilt, spearheaded the initial surgery employing this novel imaging approach. He and his team have since performed multiple surgeries as part of an extensive clinical study involving up to 50 patients. The study’s principal objective is to evaluate the long-term feasibility and clinical benefits of incorporating intraoperative PET-CT to assess tumor resections during surgery, aiming to set a new standard in cancer care.

Intraoperative PET-CT represents a significant technological leap by enabling surgeons to conduct detailed margin analysis in real-time. Traditionally, resected tumor specimens are sent to pathology labs, where comprehensive microscopic evaluations can take days to finalize before confirming whether the surgical margins are clean of cancer cells. By contrast, this new method transports the resected tissue immediately to the nearby scanner within the operating suite, supplying surgeons with rapid and critical feedback on the completeness of the cancer removal.

The innovative imaging modality capitalizes on the strengths of PET and CT technologies in unison. PET provides vital functional insights by detecting metabolic activity, using radiotracers that highlight malignant tissues due to their elevated glucose uptake. Meanwhile, the CT scan offers detailed anatomical views, outlining the tumor and its surroundings with high spatial resolution. This fusion delivers a comprehensive image, enabling surgeons to identify residual malignant cells that could remain undetectable by visual inspection alone.

During the surgical procedure, patients receive an injection of fluorodeoxyglucose (FDG), a radiopharmaceutical that mimics glucose. Cancerous cells, being metabolically hyperactive, absorb and retain FDG more than normal tissues, causing the tumor to “light up” on the PET scan. Once the tumor is excised, the specimen is scanned immediately with the Aura 10 device, and the imaging data are analyzed to determine if the edges of the removed tissue—termed margins—are free from cancerous cells. This immediate feedback empowers surgeons to decide whether additional tissue needs excision to ensure a negative margin and reduce the risk of recurrence.

Dr. Topf emphasized that the ongoing research not only tests the feasibility of using intraoperative PET-CT in the operating room but also rigorously compares its accuracy against the pathology lab’s gold standard of microscopic tissue analysis. Validation of this technology could revolutionize head and neck oncology surgeries by providing surgeons greater confidence during resections, potentially improving cure rates and sparing patients from the morbidity of incomplete removals or excessive surgery.

Nicole Jones, the research coordinator IV in the otolaryngology laboratory, highlighted the transformative clinical implications of incorporating this technology. She noted that current practices involve a time lag between surgery and pathology results, often leading to delayed decisions about follow-up treatments or surgeries. The immediate intraoperative imaging poster presented by the Aura 10 scanner could profoundly impact patient care by drastically shortening this feedback loop, allowing surgical teams to tidy up any residual cancer in a single operative session.

Such innovation redefines surgical workflows by keeping everything within the operative environment. Surgeons no longer need to leave the sterile operating theater to consult pathology results; instead, the entire cycle of tumor removal and assessment occurs seamlessly and in real-time. This integrated model is poised to enhance surgical precision, reduce reoperation rates, and improve overall patient outcomes. It also embodies a bold leap towards more personalized, data-driven surgical oncology.

From the patient perspective, Dr. Topf noted that participation in this clinical research offers a unique and compelling opportunity to benefit from cutting-edge technology without additional hospital visits or invasive testing. Using intraoperative PET-CT represents a convergence of advanced imaging and surgical techniques designed to elevate the standard of care and instill confidence in both surgeons and patients that cancer removal is as thorough and minimally invasive as possible.

The implications of this technology extend beyond head and neck cancer surgeries, potentially applying to numerous other oncologic and surgical disciplines where accurate margin assessment is critical. The real-time, intraoperative visualization of cancer metabolism and localization offers a window into personalized surgery, where every decision is informed by precise biological and anatomical data.

In summary, the integration of the Aura 10 intraoperative PET-CT scanner into head and neck cancer surgeries represents a paradigm shift in oncologic surgery. This novel approach promises to reduce positive surgical margins, lower recurrence rates, and accelerate clinical decision-making. The ongoing study at Vanderbilt University Medical Center, led by Dr. Michael Topf and his team, continues to evaluate the technology’s long-term viability and hopes to pave the way for widespread clinical adoption of intraoperative molecular imaging.

As the landscape of cancer surgery evolves, innovations like this that blend real-time molecular imaging with surgical practice could herald a new era in precision oncology, improving patient survival and quality of life through enhanced surgical accuracy and tailored treatment approaches. The success of this research may ultimately redefine how surgeons approach cancer resections and set new benchmarks for operative excellence worldwide.

Subject of Research: Advanced intraoperative imaging technology in head and neck cancer surgery

Article Title: Breakthrough Use of Intraoperative PET-CT in Head and Neck Cancer Surgery at Vanderbilt University

News Publication Date: (Information not provided)

Web References: (Information not provided)

References: (Information not provided)

Image Credits: Photo by Erin O. Smith, Vanderbilt University Medical Center

Keywords: Head and neck cancer, Otolaryngology, Intraoperative PET-CT, Surgical oncology, Cancer margin assessment, Real-time molecular imaging

University of Oklahoma researchers have embarked on a pioneering clinical investigation aimed at elucidating the role cannabis use plays in the complex process of wound healing following head and neck cancer surgeries. This novel research, co-led by Dr. Lurdes Queimado, M.D., Ph.D., and Dr. Mark Mims, M.D., seeks to fill a critical knowledge gap in medical science regarding how cannabis consumption may alter physiological recovery in patients undergoing extensive surgical procedures involving tumor excision and subsequent reconstructive efforts. With an anticipated enrollment of 220 adult patients, this prospective study promises to produce definitive, biochemically validated data to inform clinical practice.

The impetus for this study arises from the high prevalence of cannabis usage among oncologic populations, with existing surveys indicating usage rates exceeding 50% or even climbing as high as 80% in those who concurrently use tobacco products. Despite such widespread consumption, the scientific community remains largely uninformed about the implications of cannabinoids on post-operative tissue repair, immunological function, and overall recovery dynamics. Previous investigations into related topics have been retrospective, limiting the ability to infer causality or temporal relationships. Therefore, this prospective study design marks a substantial methodological advancement by tracking patients longitudinally over six months, starting at the time of their surgical therapy.

A distinctive strength of this research lies in its rigorous verification of cannabis exposure. Patients’ self-reports of cannabis usage will be corroborated by blood biomarker analyses, mitigating the common issue of reporting bias that plagues observational studies. This biochemical validation will enhance data quality and strengthen conclusions regarding potential associations between cannabis use patterns and wound healing outcomes. Furthermore, the study’s nuanced approach considers the heterogeneity of cannabis administration modes—namely smoking, vaping, and edible consumption—which possess distinct pharmacokinetic profiles and physiological impacts.

Dr. Queimado, who directs the Tobacco Regulatory Science Lab at the University of Oklahoma’s TSET Health Promotion Research Center, hypothesizes that cannabis smoking, in particular, may exert deleterious effects on wound healing. Her preliminary data from non-cancer cohorts demonstrated increased inflammatory markers and suppressed immune cell functionality among cannabis smokers, factors known to impede tissue regeneration and elevate the risk of postoperative complications. However, the clinical relevance of these findings in cancer surgery patients remains uncharted territory, prompting this comprehensive study to dissect how different modes and frequencies of cannabis use impact diverse healing parameters.

To untangle the complex interplay between cannabis and tobacco use on surgical recovery, the research protocol stratifies participants into four distinct groups: exclusive cannabis users, dual cannabis and tobacco users, exclusive tobacco users, and a control group abstaining from both substances. This stratification permits granular analysis of additive or synergistic effects of these substances on wound healing trajectories. Key clinical endpoints under meticulous observation include infection rates, bleeding incidents, wound dehiscence, scar maturation, and other medical complications.

Facial plastic and reconstructive surgeon Dr. Mark Mims emphasizes the clinical urgency underpinning this research. Physicians routinely face patient inquiries regarding cannabis use and surgical outcomes yet currently lack robust evidence to provide definitive guidance. By generating scientifically rigorous data, this study aims to empower clinicians with the knowledge necessary to counsel patients accurately, thereby optimizing perioperative management and improving prognostic assessments.

In addition to surgical recovery metrics, the study will evaluate how cannabis consumption modulates patients’ responses to adjunctive cancer therapies such as chemotherapy and radiation. These treatments intrinsically affect immune function and tissue homeostasis, and understanding cannabis interactions within this therapeutic context could reveal broader implications for comprehensive cancer care and survivorship.

Beyond oncologic surgery, the broader scientific significance of this research extends to medical conditions characterized by chronic inflammation and immunological dysfunction. Conditions such as autoimmune diseases also hinge on delicate balances between immune activation and suppression, resilience of connective tissues, and control of inflammatory cascades. Insights gleaned from this work may catalyze expanded investigations into cannabis effects in these domains, ultimately shaping therapeutic guidelines and public health policies.

This prospective cohort study by University of Oklahoma’s medical researchers not only pioneers a previously neglected area of inquiry, but also establishes a robust framework for future explorations into cannabis pharmacology and surgical science. The integration of biochemical confirmation, stratified patient groups, and longitudinal follow-up elevates the standard of research rigor, setting a precedent for subsequent studies in diverse clinical settings.

The Presbyterian Health Foundation’s funding support underscores the societal relevance and translational potential of this research endeavor. By advancing understanding at the intersection of substance use and surgical healing, the study promises to inform patient care decisions and possibly influence regulatory stances on cannabis consumption in medical populations.

As cannabis legalization expands nationwide, generating evidence-based clarity on its effects within sensitive medical contexts is critical. This University of Oklahoma-led investigation stands at the forefront of this effort, offering hope for improved clinical protocols that accommodate patient behaviors while safeguarding healing and recovery.

Subject of Research: Effects of cannabis use on wound healing following head and neck cancer surgery.

Article Title: (Not provided)

News Publication Date: (Not provided)

Web References: http://www.ouhsc.edu/

References: (Not provided)

Image Credits: University of Oklahoma

Keywords: Wound healing, Cannabis, Head and neck cancer, Inflammation, Immune system

Traditionally, reconstructing the lower jaw, especially after extensive oncological resections, has been a challenging endeavor. Surgeons typically rely on manual measurements and intraoperative adjustments to fashion reconstructive hardware and bone grafts, a process that is both time-consuming and prone to variability. The introduction of CAD/CAM represents a paradigm shift, permitting preoperative virtual surgical planning and the fabrication of highly accurate, patient-specific cutting guides and fixation plates through three-dimensional printing. This integration of digital technology affords unprecedented precision, streamlining the surgical workflow and potentially reducing the risk of complications.

The study in question evaluated outcomes from 215 patients who underwent free fibula flap mandibular reconstruction between 2012 and 2021, comparing 136 cases utilizing CAD/CAM assistance with 79 conventional procedures. These patients were primarily postoperative head and neck cancer survivors, a cohort that demands meticulous surgical planning due to the functional and aesthetic significance of mandibular restoration. The research illuminated key differences in operative efficiency and postoperative morbidity that underscore the value of CAD/CAM integration.

One of the most striking findings was the reduction in operating room time for patients treated with CAD/CAM-assisted reconstruction. On average, these surgeries were an hour shorter than those performed using traditional methods. This decrease in operative duration likely stems from the elimination of intraoperative trial-and-error hardware shaping and bone contouring. Instead, surgeons enter the procedure with precisely manufactured guides and plates that fit the patient’s unique anatomy, facilitating faster and more confident execution of complex reconstructions.

When examining immediate postoperative complications, both groups displayed comparable rates of serious events such as hemorrhage, thrombosis, and flap failure. However, a notable difference appeared in the incidence of wound dehiscence, or the reopening of surgical incisions. Patients who received CAD/CAM-assisted reconstruction experienced significantly fewer cases—7.4% compared to 16.5% in the traditional cohort. This suggests improved soft tissue management and potentially enhanced surgical precision afforded by the digital planning process.

Long-term outcomes, assessed over two to two and a half years post-surgery, revealed a particularly meaningful benefit tied to hardware management. While the majority of long-term complications did not differ dramatically between groups, the need for secondary surgeries to remove reconstructive hardware was markedly lower in the CAD/CAM cohort. Statistical adjustment for confounding factors indicated that CAD/CAM patients were 60% less likely to require hardware removal, highlighting a durable and stable reconstruction.

The underlying mechanism for this reduction in hardware-related interventions may be multifactorial. CAD/CAM enables surgeons to position fixation plates and screws accurately, minimizing stress points and optimizing biomechanical alignment. Furthermore, the precise osteotomies guided by bespoke cutting guides promote superior bone union, creating a more robust structural foundation that reduces hardware loosening, exposure, or infection risks. This synergy between precise fabrication and anatomical fidelity is a testament to the potential of integrating engineering principles within surgical practice.

Despite these clinical advantages, the study acknowledged the increased initial cost associated with CAD/CAM utilization. The authors emphasized the necessity for future research to perform comprehensive cost-effectiveness analyses, weighing the upfront technological investment against extended benefits such as fewer complications, reduced operative times, and diminished need for revision surgeries. Understanding this balance will play a crucial role in driving adoption and reimbursement policies across healthcare systems.

This research also underscores the rapidly evolving role of virtual surgical planning in reconstructive surgery. Virtual models allow surgeons to visualize complex defects in three dimensions, simulate various reconstructive scenarios, and collaborate with biomedical engineers to optimize outcomes before the first incision is made. The precision and personalization inherent in this approach resonate with the broader movement toward patient-specific treatments in medicine, promising to elevate both functional and aesthetic reconstruction paradigms.

Moreover, the study’s findings contribute empirical evidence to a growing body of literature supporting CAD/CAM technologies in craniofacial reconstruction. While previous reports have highlighted improvements in surgical accuracy and bone healing, this work advances the field by correlating these technical enhancements with tangible clinical outcomes over the long term. It represents a meaningful step toward establishing new standards of care that leverage digital innovation for complex reconstructive challenges.

Looking ahead, the continuous refinement of CAD/CAM systems, including advancements in biomaterials and 3D printing techniques, could further enhance the versatility and accessibility of this technology. Coupled with improvements in imaging modalities and software algorithms, these developments may soon allow for even more seamless integration into routine clinical workflows. Surgeons, patients, and healthcare providers alike stand to benefit from these innovations, which promise safer, faster, and more reliable reconstructive outcomes.

In conclusion, the adoption of computer-aided design and manufacturing in free fibula flap mandibular reconstruction represents a major breakthrough with demonstrable benefits. From reduced operative times and fewer wound complications to a substantial decrease in hardware removal surgeries, CAD/CAM techniques offer significant improvements over conventional methods. As this technology becomes increasingly sophisticated and economically viable, it is poised to become the new gold standard, revolutionizing how surgeons approach one of the most intricate and impactful procedures in head and neck reconstruction.

Subject of Research: Computer-Aided Design and Manufacturing (CAD/CAM) in Free Fibula Flap Mandibular Reconstruction

Article Title: Computer-Aided Design and Manufacturing in Free Fibula Reconstruction of the Mandible: Comparison of Long-Term Outcomes

News Publication Date: April 29, 2025

Web References:
https://journals.lww.com/plasreconsurg/fulltext/2025/05000/computer_aided_design_and_manufacturing_in_free.25.aspx

Keywords:
Mandible, Reconstructive surgery, Cosmetic surgery, Free fibula flap, Computer-aided design, Surgical planning, Head and neck cancer, Bone grafting, 3D printing, Virtual surgical planning, Hardware removal, Craniofacial reconstruction